Search Result
Results for "
hypoglycemic
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N7910
-
-
-
- HY-Y0004
-
-
-
- HY-15383
-
|
Others
|
Others
|
Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury .
|
-
-
- HY-W011651
-
-
-
- HY-170692
-
|
Akt
PI3K
NF-κB
|
Metabolic Disease
|
Hypoglycemic agent 3 (Compound H26), a derivative of corosolic acid, exhibits lipid-lowering and significant hypoglycemic effects and can be used as a hypoglycemic agent. Hypoglycemic agent 3 inhibits insulin resistance by targeting MCCC1 and can be used in the study of type 2 diabetes .
|
-
-
- HY-130003
-
|
Others
|
Metabolic Disease
|
Hypoglycemic agent 1 acts as a therapeutic and/or prophylactic agent for diabetes. Hypoglycemic agent 1 has an action for lowering blood sugar .
|
-
-
- HY-N7910R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Stachyose (Standard) is the analytical standard of Stachyose. This product is intended for research and analytical applications. Stachyose, a kind of oligosaccharides, act as a hypoglycemic agent[1].
|
-
-
- HY-N3613
-
|
Others
|
Metabolic Disease
|
Conduritol A is a hypoglycemic agent which inhibits the absorption of glucose and can be extracted from Gymnema sylvestre .
|
-
-
- HY-135670B
-
|
Glycosidase
|
Metabolic Disease
|
Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity .
|
-
-
- HY-135670A
-
|
Glycosidase
|
Metabolic Disease
|
β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity .
|
-
-
- HY-N12241
-
|
Others
|
Others
|
Sterebin F is a steroid isolated from the Stevia rebaudiana leaves. Sterebin F has hypoglycemic activity .
|
-
-
- HY-162893
-
|
Glycosidase
|
Metabolic Disease
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
-
- HY-101048
-
|
Bacterial
|
Infection
Metabolic Disease
|
Synthalin A sulfate is a biguanylated diamine with antibacterial and hypoglycemic properties. Synthalin A sulfate against S. aureus with a MIC of 64 μg/mL .
|
-
-
- HY-N7377
-
|
Glycosidase
|
Metabolic Disease
|
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment .
|
-
-
- HY-N4147
-
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities . Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272) .
|
-
-
- HY-W011651R
-
BZ-55 (Standard)
|
Phosphatase
Reference Standards
|
Metabolic Disease
|
Carbutamide (Standard) is the analytical standard of Carbutamide. This product is intended for research and analytical applications. Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity .
|
-
-
- HY-113631
-
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .
|
-
-
- HY-170588
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-78 (Compound 12m) is an inhibitor for α-glucosidase with a reversible, competitive IC50 6.0 μM. α-Glucosidase-IN-78 can be used in research of diabete for its hypoglycemic property .
|
-
-
- HY-163652
-
|
Others
|
Metabolic Disease
|
Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes .
|
-
-
- HY-N12647
-
|
Others
|
Infection
Inflammation/Immunology
|
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .
|
-
-
- HY-135670
-
|
Glycosidase
|
Metabolic Disease
|
Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity .
|
-
-
- HY-128574
-
|
GLUT
|
Metabolic Disease
|
GLUT4 activator 1 (Compound 26b) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM. GLUT4 activator 1 has a hypoglycemic effect. GLUT4 activator 1 can be used in diabetes research .
|
-
-
- HY-121565
-
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .
|
-
-
- HY-N11840
-
|
Glycosidase
|
Metabolic Disease
|
Mortatarin F (Compound 1) is an inhibitor of α‑glucosidase with an IC50 of 8.7 μΜ. Mortatarin F is an renylated flavonoid that can be isolated from mulberry leaves and can be used for hypoglycemic research .
|
-
-
- HY-168706
-
|
Phosphatase
|
Metabolic Disease
|
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .
|
-
-
- HY-N0661
-
-
-
- HY-122943
-
|
Fungal
Apoptosis
|
Infection
Cancer
|
Moracin D is a flavonoid that can be isolated from Morus alba. Moracin D induces cell apoptosis and shows hypoglycemic, antiadipogenic, antifungal and antitumor effects. Moracin D can be used for fungal infection and breast cancer research .
|
-
-
- HY-126067
-
|
Glycosidase
Apoptosis
|
Inflammation/Immunology
|
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that inhibits α-glucosidase and acts as a hypoglycemic agent. (-)-Pinoresinol has some anti-inflammatory effects and acts as a chemopreventive agent, inducing increased apoptosis and cell cycle G2/M arrest .
|
-
-
- HY-156830A
-
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
(4′R)-TGR5 Receptor Agonist 4 is the R enantiomer of TGR5 Receptor Agonist 4 (HY-156830). TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC50 for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .
|
-
-
- HY-128923
-
3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride
|
PEPCK
|
Metabolic Disease
|
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (Ki: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides .
|
-
-
- HY-N0820
-
Catalpol
Maximum Cited Publications
10 Publications Verification
Catalpinoside
|
HBV
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
|
-
-
- HY-Y0624
-
|
Endogenous Metabolite
Mitochondrial Metabolism
|
Metabolic Disease
|
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .
|
-
-
- HY-N0661R
-
-
-
- HY-172811
-
|
GCGR
|
Metabolic Disease
|
DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study .
|
-
-
- HY-N8264
-
|
TRP Channel
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Moringin is a potent and selective TRPA1 ion channel natural agonist with an EC50 of 3.14 μM. Moringin does not activate or activates very weakly the vanilloids somatosensory channels TRPV1, TRPV2, TRPV3 and TRPV4, and the melastatin cooling receptor TRPM8. Moringin has hypoglycemic, antimicrobial, anti-inflammatory, anticancer and neuroprotection activities .
|
-
-
- HY-N5086
-
-
-
- HY-N0820R
-
|
HBV
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Catalpol (Standard) is the analytical standard of Catalpol. This product is intended for research and analytical applications. Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects .
|
-
-
- HY-172120
-
|
GPR119
|
Metabolic Disease
|
GPR119 agonist 3 (Compound 21b) is an orally active agonist of GPR119 with an EC50 value of 3.8 nM for hGPR119. Additionally, GPR119 agonist 3 exhibits hypoglycemic effects and can be used in research on type 2 diabetes and obesity .
|
-
-
- HY-128447
-
|
Endogenous Metabolite
SOD
NF-κB
GLUT
|
Metabolic Disease
Inflammation/Immunology
|
Allyl methyl sulfide is an orally active organic sulfide. Allyl methyl sulfide is one of the main active ingredients in garlic volatile metabolites. Allyl methyl sulfide can be extracted from garlic. Allyl methyl sulfide enhances SOD activity, inhibits NF-κB signaling pathway, and upregulates pancreatic GLUT2 expression. Allyl methyl sulfide has significant antioxidant, anti-inflammatory and hypoglycemic activities. Allyl methyl sulfide can be used in the research of diabetes and its complications .
|
-
-
- HY-W011220
-
ADD-3878; U-63287
|
PPAR
|
Cardiovascular Disease
Cancer
|
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .
|
-
-
- HY-128447R
-
|
Reference Standards
Endogenous Metabolite
SOD
NF-κB
GLUT
|
Metabolic Disease
Inflammation/Immunology
|
Allyl methyl sulfide (Standard) is the analytical standard of Allyl methyl sulfide (HY-128447). This product is intended for research and analytical applications. Allyl methyl sulfide is an orally active organic sulfide. Allyl methyl sulfide is one of the main active ingredients in garlic volatile metabolites. Allyl methyl sulfide can be extracted from garlic. Allyl methyl sulfide enhances SOD activity, inhibits NF-κB signaling pathway, and upregulates pancreatic GLUT2 expression. Allyl methyl sulfide has significant antioxidant, anti-inflammatory and hypoglycemic activities. Allyl methyl sulfide can be used in the research of diabetes and its complications .
|
-
-
- HY-150723
-
|
Glycosidase
|
Metabolic Disease
|
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .
|
-
-
- HY-N0416
-
-
-
- HY-N0926A
-
Columbamin chloride; Dehydroisocorypalmine chloride
|
Cytochrome P450
Apoptosis
Parasite
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Columbamine (Columbamin; Dehydroisocorypalmine) chloride is an organic heterotetracyclic alkaloid extracted from plants. Columbamine chloride is a metabolite of Berberine (HY-N0716). Columbamine chloride inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine chloride induces apoptosis in cancer cells. Columbamine chloride can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .
|
-
-
- HY-N0926
-
Columbamin; Dehydroisocorypalmine
|
Cytochrome P450
Apoptosis
Parasite
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Columbamine (Columbamin; Dehydroisocorypalmine) is an organic heterotetracyclic alkaloid extracted from plants. Columbamine is a metabolite of Berberine (HY-N0716). Columbamine inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine induces apoptosis in cancer cells. Columbamine can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .
|
-
-
- HY-U00012
-
SQ 15860; Serbose; Subose
|
Others
|
Metabolic Disease
|
Glyhexamide is an effective hypoglycemic agent in adult diabetics.
|
-
-
- HY-N0416R
-
-
-
- HY-173217
-
|
PPAR
Phosphatase
|
Cardiovascular Disease
Metabolic Disease
|
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .
|
-
-
- HY-B1103
-
-
-
- HY-B0920
-
-
- HY-B1236
-
-
- HY-B0401S
-
-
- HY-B0401S1
-
-
- HY-N9725
-
16ξ-Hydroxycleroda-3,13-dien-15,16-olide
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
|
-
- HY-B1103R
-
(±)-Hydroxyhexamid (Standard)
|
Reference Standards
Drug Metabolite
|
Cardiovascular Disease
|
Hydroxyhexamide (Standard) is an analytical standard for Hydroxyhexamide. This product is intended for research and analytical applications. Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
|
-
- HY-B1429
-
-
- HY-N6653
-
-
- HY-B1429R
-
|
Reference Standards
Na+/K+ ATPase
|
Endocrinology
|
Chlorpropamide (Standard) is the analytical standard of Chlorpropamide. This product is intended for research and analytical applications. Chlorpropamide is an oral hypoglycemic agent studied in non-insulin-dependent diabetes mellitus (NIDDM).
|
-
- HY-105935
-
-
- HY-N0205
-
Anemoside B4
|
Others
|
Cancer
|
Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.
|
-
- HY-B0089
-
BAY g 5421
|
Glycosidase
|
Metabolic Disease
Cancer
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N2000
-
|
HIV
|
Infection
Inflammation/Immunology
Cancer
|
Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities . Bellidifolin also acts as a viral protein R (Vpr) inhibitor .
|
-
- HY-B0089A
-
Bay-g 5421 sulfate
|
Glycosidase
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-162758
-
|
Aldose Reductase
|
Metabolic Disease
|
ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes .
|
-
- HY-156830
-
-
- HY-114683
-
|
TGF-beta/Smad
|
Cardiovascular Disease
|
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .
|
-
- HY-N0807R
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .
|
-
- HY-P4860
-
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-105935R
-
Cyanidin 3-rutinoside chloride (Standard); Cyanidin 3-O-rutinoside chloride (Standard); Sambucin chloride (Standard)
|
Reference Standards
NF-κB
PPAR
Reactive Oxygen Species
FAK
p38 MAPK
ERK
JNK
|
Metabolic Disease
Inflammation/Immunology
|
Keracyanin (chloride) (Standard) is the analytical standard of Keracyanin (chloride). This product is intended for research and analytical applications. Keracyanin chloride inhibits NF-κB/FAK/MAPK signaling pathway. Keracyanin chloride exhibits antioxidant, anti-inflammatory and hypoglycemic effects, and is orally active .
|
-
- HY-148529
-
(±)-DG5128 free base; DG5128 free base
|
Adrenergic Receptor
|
Cardiovascular Disease
Metabolic Disease
|
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .
|
-
- HY-173183
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-87 (Compound 11c) is an orally active α-glucosidase inhibitor with an IC50 value of 119.7 μM. α-Glucosidase-IN-87 has hypoglycemic activity and can be used in the research of metabolic diseases such as diabetes .
|
-
- HY-121323R
-
|
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-B0089R
-
|
Glycosidase
|
Metabolic Disease
Cancer
|
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N0655
-
3-O-Methyl-D-chiro-inositol
|
Influenza Virus
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .
|
-
- HY-162136
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED50 of 0.58 mg/kg
|
-
- HY-N0761
-
-
- HY-N0299
-
|
Endogenous Metabolite
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
Stachyose hydrate is an orally active prebiotic that enhances the growth and activity of beneficial bacteria. Stachyose hydrate has hypoglycemic effects and can improve inflammation by regulating gut microbiota. In addition, Stachyose hydrate can induce plant cell apoptosis (Apoptosis). Stachyose hydrate can be used in research on inflammation, gastrointestinal diseases, and agriculture .
|
-
- HY-117985A
-
DA-1229 hydrochloride
|
Dipeptidyl Peptidase
|
Metabolic Disease
Endocrinology
|
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
|
-
- HY-N2229
-
|
Cytochrome P450
Fungal
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50
= 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively .
|
-
- HY-N2229R
-
|
Cytochrome P450
Fungal
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
Rhapontigenin (Standard) is the analytical standard of Rhapontigenin. This product is intended for research and analytical applications. Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50
= 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively .
|
-
- HY-B0089S
-
BAY g 5421-d4
|
Isotope-Labeled Compounds
Glycosidase
|
Metabolic Disease
Cancer
|
Acarbose-d4 (BAY g 5421-d4) is deuterium labeled Acarbose. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
- HY-N0655R
-
|
Influenza Virus
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
D-Pinitol (Standard) is the analytical standard of D-Pinitol. This product is intended for research and analytical applications. D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .
|
-
- HY-144035
-
|
GCGR
|
Cancer
|
GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
|
-
- HY-N7241
-
|
Others
|
Endocrinology
|
Saudin, derived from Clutia lanceolata, is a hypoglycemic compound that significantly enhances glucose-triggered insulin release from murine pancreatic islets. It belongs to a group of new diterpenoids with a distinct tetracyclic core, suggesting potential as a therapeutic agent for diabetes treatment. Proposed biosynthetic pathways outline alternative cyclization routes from a common precursor, with Lanceolide P (16) identified as a promising lead compound for further development in managing diabetes .
|
-
- HY-N5083
-
-
- HY-P10312
-
|
GLP Receptor
|
Metabolic Disease
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
-
- HY-163005
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
|
-
- HY-173503
-
|
GLUT
|
Metabolic Disease
|
DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .
|
-
- HY-N0761R
-
3-Hydroxy-4-methoxycinnamic acid (Standard)
|
Adrenergic Receptor
Influenza Virus
|
Infection
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
Isoferulic acid (Standard) (3-Hydroxy-4-methoxycinnamic acid (Standard)) is the analytical standard of Isoferulic acid (HY-N0761). This product is intended for research and analytical applications. Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes .
|
-
- HY-Y0337
-
Cysteine
|
Endogenous Metabolite
ERK
|
Neurological Disease
Metabolic Disease
Cancer
|
L-Cysteine (Cysteine) is an orally active conditionally essential amino acid with hypoglycemic effects, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine promotes the proliferation and differentiation of neural stem cells via the CBS/H2S pathway. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. L-Cysteine can be used as an anorectic agent .
|
-
- HY-Y0624R
-
|
Reference Standards
Endogenous Metabolite
Mitochondrial Metabolism
|
Metabolic Disease
|
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.
|
-
- HY-I0786
-
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). (2S,4R)-Teneligliptin increases the plasma concentration of active glucagon-like peptide-1 (GLP-1), which promotes insulin secretion in response to elevated blood glucose levels, exerting hypoglycemic activity. (2S,4R)-Teneligliptin is promising for research of type 2 diabetes .
|
-
- HY-144034
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
|
-
- HY-144033
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
|
-
- HY-144717
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research .
|
-
- HY-159944
-
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
|
-
- HY-19904A
-
(+/-)-LY2409021
|
Endogenous Metabolite
|
Metabolic Disease
|
(+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .
|
-
- HY-N5083R
-
-
- HY-N0807
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .
|
-
- HY-147246
-
HTD1801; BUDCA
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
|
-
- HY-126969
-
|
PPAR
|
Metabolic Disease
|
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
|
-
- HY-144718
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
|
-
- HY-144716
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
|
-
- HY-144713
-
|
Phosphatase
|
Metabolic Disease
|
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
|
-
- HY-P3580
-
Human N-acetyl GIP
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
|
-
- HY-P3580A
-
Human N-acetyl GIP TFA
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4860
-
|
Akt
Gli
JNK
PKA
|
Metabolic Disease
|
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway .
|
-
- HY-P3580A
-
Human N-acetyl GIP TFA
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
|
-
- HY-P10312
-
|
GLP Receptor
|
Metabolic Disease
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
-
- HY-P3580
-
Human N-acetyl GIP
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0401S
-
|
Tolbutamide-d9 is the deuterium labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.
|
-
-
- HY-B0401S1
-
|
Tolbutamide- 13C is the 13C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.
|
-
-
- HY-B0089S
-
|
Acarbose-d4 (BAY g 5421-d4) is deuterium labeled Acarbose. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: